TY - JOUR
T1 - Management and prognosis of atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report
AU - Fumagalli, Stefano
AU - Said, Salah A.
AU - Laroche, Cecile
AU - Gabbai, Debbie
AU - Boni, Serena
AU - Marchionni, Niccolo
AU - Boriani, Giuseppe
AU - Maggioni, Aldo P.
AU - Musialik-Lydka, Agata
AU - Sokal, Adam
AU - Petersen, Jens
AU - Crijns, Harry J. G. M.
AU - Lip, Gregory Y. H.
AU - EORP-AF Gen Pilot Registry Investi
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Aims Diabetes mellitus (DM) is one of the most important cardiovascular risk factors. The aim of this study was to evaluate clinical correlates of DM, including management and outcomes, in the EURObservational Research Programme (EORP)-Atrial Fibrillation (AF) General Pilot (EORP-AF) Registry of the European Society of Cardiology. Methods and results We studied consecutive patients (N = 3101) enrolled in 70 centres of nine European countries between February 2012 and March 2013, and compared diabetics with non-diabetics during a 1-year follow-up. In the overall cohort, the prevalence of DM was 20.6%. Diabetics were older (71 +/- 9 vs. 68 +/- 12 years, P < 0.0001) and had more comorbidities, higher CHA(2)DS(2)-VASc score (4.6 +/- 1.6 vs. 2.9 +/- 1.7, P < 0.0001) and higher prevalence of permanent AF (21.5 vs. 16.0%, P = 0.0022). Quality of life amongst DM patients was significantly worse [atrial fibrillation quality of life questionnaire (AF-QoL) score 45.2 +/- 19.2 vs. 49.3 +/- 20.1, P < 0.0001]. Amongst diabetics, the use of electrical cardioversion (16.2 vs. 24.6%, P < 0.0001) and catheter ablation (3.3 vs. 8.6%, P < 0.0001) was lower, whilst oral anticoagulants were more often prescribed (84.3 vs. 78.9%, P = 0.0027). After one year, diabetic patients had significantly higher all-cause (11.9 vs. 4.9%, P < 0.0001), cardiovascular (6.2 vs. 1.9%, P < 0.0001), and non-cardiovascular mortality (2.3 vs. 1.1%, P = 0.0356). Conclusion In AF patients, DM is associated with a higher prevalence of comorbidities and a worse quality of life. After one year, all-cause, cardiovascular, and non-cardiovascular mortality were significantly higher in diabetic subjects.
AB - Aims Diabetes mellitus (DM) is one of the most important cardiovascular risk factors. The aim of this study was to evaluate clinical correlates of DM, including management and outcomes, in the EURObservational Research Programme (EORP)-Atrial Fibrillation (AF) General Pilot (EORP-AF) Registry of the European Society of Cardiology. Methods and results We studied consecutive patients (N = 3101) enrolled in 70 centres of nine European countries between February 2012 and March 2013, and compared diabetics with non-diabetics during a 1-year follow-up. In the overall cohort, the prevalence of DM was 20.6%. Diabetics were older (71 +/- 9 vs. 68 +/- 12 years, P < 0.0001) and had more comorbidities, higher CHA(2)DS(2)-VASc score (4.6 +/- 1.6 vs. 2.9 +/- 1.7, P < 0.0001) and higher prevalence of permanent AF (21.5 vs. 16.0%, P = 0.0022). Quality of life amongst DM patients was significantly worse [atrial fibrillation quality of life questionnaire (AF-QoL) score 45.2 +/- 19.2 vs. 49.3 +/- 20.1, P < 0.0001]. Amongst diabetics, the use of electrical cardioversion (16.2 vs. 24.6%, P < 0.0001) and catheter ablation (3.3 vs. 8.6%, P < 0.0001) was lower, whilst oral anticoagulants were more often prescribed (84.3 vs. 78.9%, P = 0.0027). After one year, diabetic patients had significantly higher all-cause (11.9 vs. 4.9%, P < 0.0001), cardiovascular (6.2 vs. 1.9%, P < 0.0001), and non-cardiovascular mortality (2.3 vs. 1.1%, P = 0.0356). Conclusion In AF patients, DM is associated with a higher prevalence of comorbidities and a worse quality of life. After one year, all-cause, cardiovascular, and non-cardiovascular mortality were significantly higher in diabetic subjects.
KW - Atrial fibrillation
KW - Diabetes mellitus
KW - Elderly
KW - Oral anticoagulants
KW - Prognosis
KW - RISK STRATIFICATION
KW - PREDICTING STROKE
KW - INDEPENDENT RISK
KW - MELLITUS
KW - OUTCOMES
KW - COHORT
KW - DISEASE
KW - THROMBOEMBOLISM
KW - POPULATION
KW - VALIDATION
U2 - 10.1093/ehjcvp/pvx037
DO - 10.1093/ehjcvp/pvx037
M3 - Article
C2 - 29309557
SN - 2055-6837
VL - 4
SP - 172
EP - 179
JO - European Heart Journal-Cardiovascular Pharmacotherapy
JF - European Heart Journal-Cardiovascular Pharmacotherapy
IS - 3
ER -